{
    "info": {
        "nct_id": "NCT04502030",
        "official_title": "Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia (\"PRO-SID\" Study)",
        "inclusion_criteria": "1. Treatment-naïve or relapsed/refractory CLL patients undergoing CLL antineoplastic treatment. Diagnosis of B-cell CLL established according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and documented within medical records.\n2. Hypogammaglobulinemia (IgG levels <5 g/L) as confirmed by the Central Laboratory.\n3. ≥18 years of age.\n4. Voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. IgG treatment within 3 months prior to Screening.\n2. Antibiotic prophylaxis and/or treatment within 7 days prior to Baseline (with the exception of trimethoprim-sulfamethoxazole [TMP/SMX], diaminodiphenyl sulfone [dapsone] and pentamidine inhalation).\n3. Current major infection or >1 major infection in the previous 6 months before Baseline.\n4. History of anaphylaxis or severe systemic response to immunoglobulin, blood or plasma-derived products or any Panzyga component.\n5. History of a non-CLL malignancy or other medical condition with life-expectancy of less than two years.\n6. Severe liver disease, with signs of ascites and/or hepatic encephalopathy.\n7. Severe kidney disease (as defined by estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2).\n8. Body weight >140 kg.\n9. Eastern Cooperative Oncology Group (ECOG) performance score of >2 (Appendix 1).\n10. Female patients of childbearing potential unwilling to use a protocol-required method of contraception (as per protocol section 7.3.9 b) from the Screening Visit throughout the study treatment period and for 30 days following the last dose of study drug.\n11. Human immunodeficiency virus (HIV) infection at Screening (defined for the study as positive HIV antibody test).\n12. Patients found to be chronic carriers of hepatitis B virus (HBV), defined by positive surface antigen (HBsAg), positive Hepatitis B core antibodies (HBcAb) and/or low HBV titers, who will not receive targeted antiviral therapy while undergoing CLL therapy, and patients with active HBV, defined as high HBV titers.\n13. Uncontrolled hepatitis C infection at Screening (defined for the study as positive hepatitis virus C [HCV] polymerase chain reaction [PCR]).\n14. Pregnant and lactating women.\n15. Subjects with a history of thromboembolic events (TEE) such as deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, transient ischemic attack, peripheral artery disease (Fontaine IV) within 6 months before Baseline.\n16. Planned or ongoing immunosuppressive treatment (other than for CLL or corticosteroids) or other forbidden medication during the entire study duration after study enrollment.\n17. Participation in another interventional clinical trial that is either blinded or involves an investigational (not approved) product within 3 months before Baseline or during the course of the clinical study. Participation in observational clinical trials or open-label trials involving an approved product may be permitted after consultation with the medical monitor.\n18. Known IgA deficiency with antibodies to IgA.\n19. Known blood hyperviscosity, or other hypercoagulable states.\n20. Patients unable or unwilling to understand or comply with the study protocol.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Hypogammaglobulinemia (IgG levels <5 g/L) as confirmed by the Central Laboratory.",
            "criterions": [
                {
                    "exact_snippets": "Hypogammaglobulinemia (IgG levels <5 g/L) as confirmed by the Central Laboratory",
                    "criterion": "IgG levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "g/L"
                            }
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": "Central Laboratory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted.",
            "criterions": [
                {
                    "exact_snippets": "Voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "voluntariness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "fully informed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "written",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "obtained before study-related procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Treatment-naïve or relapsed/refractory CLL patients undergoing CLL antineoplastic treatment. Diagnosis of B-cell CLL established according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and documented within medical records.",
            "criterions": [
                {
                    "exact_snippets": "Treatment-naïve or relapsed/refractory CLL patients undergoing CLL antineoplastic treatment",
                    "criterion": "CLL treatment status",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": [
                                "treatment-naïve",
                                "relapsed/refractory"
                            ]
                        },
                        {
                            "requirement_type": "current treatment",
                            "expected_value": "undergoing CLL antineoplastic treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of B-cell CLL established according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and documented within medical records",
                    "criterion": "B-cell CLL diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "B-cell CLL"
                        },
                        {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "iwCLL criteria"
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": "documented within medical records"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. ≥18 years of age.",
            "criterions": [
                {
                    "exact_snippets": "≥18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "9. Eastern Cooperative Oncology Group (ECOG) performance score of >2 (Appendix 1).",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance score of >2",
                    "criterion": "ECOG performance score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Pregnant and lactating women.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating women",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Current major infection or >1 major infection in the previous 6 months before Baseline.",
            "criterions": [
                {
                    "exact_snippets": "Current major infection",
                    "criterion": "major infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "current"
                        }
                    ]
                },
                {
                    "exact_snippets": ">1 major infection in the previous 6 months before Baseline",
                    "criterion": "major infection",
                    "requirements": [
                        {
                            "requirement_type": "count",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "infections"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "previous 6 months before Baseline"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Severe liver disease, with signs of ascites and/or hepatic encephalopathy.",
            "criterions": [
                {
                    "exact_snippets": "Severe liver disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "signs of ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "signs of ... hepatic encephalopathy",
                    "criterion": "hepatic encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. History of a non-CLL malignancy or other medical condition with life-expectancy of less than two years.",
            "criterions": [
                {
                    "exact_snippets": "History of a non-CLL malignancy",
                    "criterion": "non-CLL malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other medical condition with life-expectancy of less than two years",
                    "criterion": "other medical condition with life-expectancy",
                    "requirements": [
                        {
                            "requirement_type": "life-expectancy",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Planned or ongoing immunosuppressive treatment (other than for CLL or corticosteroids) or other forbidden medication during the entire study duration after study enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Planned or ongoing immunosuppressive treatment (other than for CLL or corticosteroids) ... during the entire study duration after study enrollment.",
                    "criterion": "immunosuppressive treatment",
                    "requirements": [
                        {
                            "requirement_type": "planned_or_ongoing",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication_exception",
                            "expected_value": [
                                "CLL",
                                "corticosteroids"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "entire study duration after study enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "other forbidden medication during the entire study duration after study enrollment.",
                    "criterion": "forbidden medication",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "entire study duration after study enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Female patients of childbearing potential unwilling to use a protocol-required method of contraception (as per protocol section 7.3.9 b) from the Screening Visit throughout the study treatment period and for 30 days following the last dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to use a protocol-required method of contraception (as per protocol section 7.3.9 b) from the Screening Visit throughout the study treatment period and for 30 days following the last dose of study drug",
                    "criterion": "use of protocol-required contraception",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "from the Screening Visit throughout the study treatment period and for 30 days following the last dose of study drug"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Known blood hyperviscosity, or other hypercoagulable states.",
            "criterions": [
                {
                    "exact_snippets": "Known blood hyperviscosity",
                    "criterion": "blood hyperviscosity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other hypercoagulable states",
                    "criterion": "hypercoagulable states",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Severe kidney disease (as defined by estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2).",
            "criterions": [
                {
                    "exact_snippets": "Severe kidney disease (as defined by estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2)",
                    "criterion": "kidney disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2",
                    "criterion": "estimated glomerular filtration rate (eGFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "mL/min/1.73 m2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Patients unable or unwilling to understand or comply with the study protocol.",
            "criterions": [
                {
                    "exact_snippets": "Patients unable ... to understand ... the study protocol",
                    "criterion": "ability to understand study protocol",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients ... unwilling to ... comply with the study protocol",
                    "criterion": "willingness to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients ... unable ... to ... comply with the study protocol",
                    "criterion": "ability to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Uncontrolled hepatitis C infection at Screening (defined for the study as positive hepatitis virus C [HCV] polymerase chain reaction [PCR]).",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hepatitis C infection at Screening",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "defined for the study as positive hepatitis virus C [HCV] polymerase chain reaction [PCR]",
                    "criterion": "hepatitis C virus (HCV) PCR result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Known IgA deficiency with antibodies to IgA.",
            "criterions": [
                {
                    "exact_snippets": "Known IgA deficiency",
                    "criterion": "IgA deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "antibodies to IgA",
                    "criterion": "antibodies to IgA",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. IgG treatment within 3 months prior to Screening.",
            "criterions": [
                {
                    "exact_snippets": "IgG treatment within 3 months prior to Screening.",
                    "criterion": "IgG treatment",
                    "requirements": [
                        {
                            "requirement_type": "exposure timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of anaphylaxis or severe systemic response to immunoglobulin, blood or plasma-derived products or any Panzyga component.",
            "criterions": [
                {
                    "exact_snippets": "History of anaphylaxis or severe systemic response to immunoglobulin, blood or plasma-derived products or any Panzyga component.",
                    "criterion": "anaphylaxis or severe systemic response to immunoglobulin, blood or plasma-derived products, or any Panzyga component",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Subjects with a history of thromboembolic events (TEE) such as deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, transient ischemic attack, peripheral artery disease (Fontaine IV) within 6 months before Baseline.",
            "criterions": [
                {
                    "exact_snippets": "history of thromboembolic events (TEE) such as deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, transient ischemic attack, peripheral artery disease (Fontaine IV) within 6 months before Baseline",
                    "criterion": "history of thromboembolic events",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "event_type",
                            "expected_value": [
                                "deep vein thrombosis",
                                "pulmonary embolism",
                                "myocardial infarction",
                                "ischemic stroke",
                                "transient ischemic attack",
                                "peripheral artery disease (Fontaine IV)"
                            ]
                        },
                        {
                            "requirement_type": "time_since_event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Participation in another interventional clinical trial that is either blinded or involves an investigational (not approved) product within 3 months before Baseline or during the course of the clinical study. Participation in observational clinical trials or open-label trials involving an approved product may be permitted after consultation with the medical monitor.",
            "criterions": [
                {
                    "exact_snippets": "Participation in another interventional clinical trial that is either blinded or involves an investigational (not approved) product within 3 months before Baseline or during the course of the clinical study.",
                    "criterion": "participation in another interventional clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "trial type",
                            "expected_value": "interventional"
                        },
                        {
                            "requirement_type": "blinding or investigational product",
                            "expected_value": [
                                "blinded",
                                "involves an investigational (not approved) product"
                            ]
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months before Baseline"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time window (during study)",
                            "expected_value": "during the course of the clinical study"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participation in observational clinical trials or open-label trials involving an approved product may be permitted after consultation with the medical monitor.",
                    "criterion": "participation in observational or open-label clinical trials involving an approved product",
                    "requirements": [
                        {
                            "requirement_type": "trial type",
                            "expected_value": [
                                "observational",
                                "open-label"
                            ]
                        },
                        {
                            "requirement_type": "product approval status",
                            "expected_value": "approved"
                        },
                        {
                            "requirement_type": "permission",
                            "expected_value": "may be permitted after consultation with the medical monitor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Patients found to be chronic carriers of hepatitis B virus (HBV), defined by positive surface antigen (HBsAg), positive Hepatitis B core antibodies (HBcAb) and/or low HBV titers, who will not receive targeted antiviral therapy while undergoing CLL therapy, and patients with active HBV, defined as high HBV titers.",
            "criterions": [
                {
                    "exact_snippets": "chronic carriers of hepatitis B virus (HBV), defined by positive surface antigen (HBsAg), positive Hepatitis B core antibodies (HBcAb) and/or low HBV titers",
                    "criterion": "chronic hepatitis B virus (HBV) carrier status",
                    "requirements": [
                        {
                            "requirement_type": "HBsAg status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "HBcAb status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "HBV titer",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "low"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic carriers of hepatitis B virus (HBV)...who will not receive targeted antiviral therapy while undergoing CLL therapy",
                    "criterion": "targeted antiviral therapy during CLL therapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt of targeted antiviral therapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with active HBV, defined as high HBV titers",
                    "criterion": "active hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "HBV titer",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "high"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Human immunodeficiency virus (HIV) infection at Screening (defined for the study as positive HIV antibody test).",
            "criterions": [
                {
                    "exact_snippets": "Human immunodeficiency virus (HIV) infection at Screening (defined for the study as positive HIV antibody test)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic method",
                            "expected_value": "positive HIV antibody test"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Antibiotic prophylaxis and/or treatment within 7 days prior to Baseline (with the exception of trimethoprim-sulfamethoxazole [TMP/SMX], diaminodiphenyl sulfone [dapsone] and pentamidine inhalation).",
            "criterions": [
                {
                    "exact_snippets": "Antibiotic prophylaxis and/or treatment within 7 days prior to Baseline (with the exception of trimethoprim-sulfamethoxazole [TMP/SMX], diaminodiphenyl sulfone [dapsone] and pentamidine inhalation)",
                    "criterion": "antibiotic prophylaxis and/or treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to Baseline"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "trimethoprim-sulfamethoxazole [TMP/SMX]",
                                "diaminodiphenyl sulfone [dapsone]",
                                "pentamidine inhalation"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Body weight >140 kg.",
            "criterions": [
                {
                    "exact_snippets": "Body weight >140 kg.",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 140,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}